Direct answer
Sterilization kills organisms. Depyrogenation destroys or removes the endotoxin those organisms leave behind. A dead Gram-negative cell still carries the lipopolysaccharide that causes a pyrogenic response, so a container can be sterile and still fail a parenteral release specification.
The practical consequence is that depyrogenation validation is a separate exercise from sterilization validation, run against a different acceptance criterion and a different source document. FDA asks for a demonstrated reduction of endotoxin content by at least 99.9 percent, or three logs[1]. USP takes a lethality-value route instead and states that a dry heat process delivering the equivalent of 250 °C for 30 minutes needs no endotoxin challenge at all[4]. EU GMP Annex 1 (2022) contains no log-reduction figure anywhere in its text[3]. Those three positions are not interchangeable, and citing the wrong one in a protocol is the most common finding on this subject.
Where each depyrogenation validation requirement actually comes from
Most published comparisons on this topic attribute the three-log rule to EU GMP Annex 1. That attribution is wrong, and it matters, because an inspector reading a protocol that cites Annex 1 for a number Annex 1 does not contain will read the rest of the protocol differently.
The 2022 revision of Annex 1, effective 25 August 2023, mentions depyrogenation once in an operational context — “Where possible, items should be sterilised and passed into these areas through double-ended sterilisers (e.g. through a double-door autoclave or depyrogenation oven/tunnel) sealed into the wall” (paragraph 4.11) — and sets an outcome expectation for containers in paragraph 8.2: “Primary packaging containers and components should be cleaned using validated processes to ensure that particle, endotoxin/pyrogen and bioburden contamination is appropriately controlled.” The phrase “log reduction” does not appear in the document[3].
| Requirement as usually stated | Where it really comes from | Exact position |
|---|---|---|
| Depyrogenation must achieve a 3-log (99.9%) endotoxin reduction | FDA 2004 Aseptic Processing guidance, Containers/Closures | “Validation study data should demonstrate that the process reduces the endotoxin content by at least 99.9 percent (3 logs)”[1] |
| The challenge is applied by spiking containers with endotoxin | FDA 2004 same section | “The adequacy of the depyrogenation process can be assessed by spiking containers and closures with known quantities of endotoxin”[1] |
| A validated dry heat cycle needs no endotoxin challenge | USP ⟨1228.1⟩ lethality-value route | “USP considers any process that yields an FH NLT 30 min during the exposure period to require no endotoxin challenge”[4] |
| Annex 1 requires a 3-log reduction | not supported no such text | Annex 1 (2022) contains no occurrence of “log reduction”; depyrogenation appears in para 4.11, endotoxin control in para 8.2[3] |
| Residual endotoxin acceptance on a challenged unit | USP commentary on ⟨1228.1⟩ | “the amount of residual endotoxin measured per sample is NMT 0.1 EU”[5] |
| Endotoxin limit for Water for Injection | FDA ITG Bacterial Endotoxins/Pyrogens | “Water for Injection, Sterile Water for Injection and Sterile Water for Irrigation have an allowable endotoxin limit of 0.25 Endotoxin Units (EU)/ml”[2] |
Swipe the table sideways on a phone. Badges marked not supported flag a claim that circulates widely but is not in the cited instrument.
How to use this in a protocol. Pick one acceptance route and name it. If the site runs the FDA route, the protocol cites the 2004 aseptic processing guidance and includes endotoxin-challenge units. If it runs the USP lethality route, the protocol cites ⟨1228.1⟩ and carries the F-value calculation with the thermocouple data that supports it. Citing both and delivering neither is what produces an observation. Annex 1 is cited for the operational requirements it does state — pass-through design, Grade A protection, contamination control strategy — not for a number.
Depyrogenation vs sterilization: what each process removes
The two processes are commonly run in the same equipment, which is why they are confused. They are not the same objective, and a cycle qualified for one is not automatically qualified for the other — although, as set out below, the direction of that asymmetry runs one way only.
| Attribute | Sterilization | Depyrogenation |
|---|---|---|
| Target | Viable microorganisms, including bacterial spores | Bacterial endotoxin (lipopolysaccharide) and other pyrogens |
| Nature of the target | Living; can be killed | Not living; a heat-stable molecule that must be destroyed or physically removed |
| Heat resistance | Lower | Higher. “Bacterial endotoxins are more resistant to the effects of dry heat than are even the most heat-resistant bacterial spores”[4] |
| Typical dry heat condition | Lower temperature, longer hold | 250 °C / 30 min (FH 30)[4] |
| Acceptance criterion | Sterility assurance demonstrated by the applicable sterilization standard | 3-log endotoxin reduction (FDA route)[1] or FH not less than 30 (USP route)[4] |
| Biological/chemical indicator | Biological indicator carrying spores | Endotoxin indicator unit; USP ⟨1228.5⟩ governs these[6] |
| Governing standard | ISO 17665:2024 (moist heat)[8]; ISO 20857:2010 (dry heat)[9] | USP ⟨1228⟩ family; PDA Technical Report No. 3 (Revised 2013)[10] |
The asymmetry that trips people up. Because endotoxin is more heat-resistant than spores, a dry heat cycle validated for depyrogenation will also sterilize — USP states that such processes “can also be counted upon to reliably sterilize materials”[4]. The reverse is not true. An autoclave cycle at 121 °C destroys spores and leaves endotoxin substantially intact. Moist heat is a sterilization process, not a depyrogenation process, and treating a validated autoclave load as depyrogenated is a design error, not a documentation gap. If you are qualifying steam equipment, see our note on the working principle of an autoclave.
The lethality-value model for dry heat
Sterilization engineers are used to F0: accumulated lethality expressed as equivalent minutes at 121 °C. Dry heat depyrogenation uses the same idea against a different reference point. One unit of depyrogenation lethality is the effect of one minute at 250 °C, which is why the classic cycle of 250 °C for 30 minutes is described as delivering a total of 30[4]. USP commentary makes the analogy explicit: this value “is to depyrogenation as what F0 is to steam sterilization”[5].
Two practical cautions before you build this into a protocol.
| Parameter | Value | Basis and status |
|---|---|---|
| Reference temperature | 250 °C | compendial one lethality unit equals one minute at 250 °C[4][5] |
| No-challenge threshold | NLT 30 | compendial USP ⟨1228.1⟩: no endotoxin challenge required above this[4] |
| Notation | FH or FD | check source the 2014 chapter text uses FH[4]; USP commentary uses FD[5]. Use the notation in the edition of ⟨1228.1⟩ current at your site and state it in the protocol |
| z-value | see note | check source the 2014 chapter text names a standard z of 50 °C[4], but published destruction kinetics differ by study and by substrate[11][12]. Do not adopt a z-value from a blog. Take it from the current compendial text or from your own kinetic data, and record the source in the protocol |
| Equivalent cited conditions | 650 °C / 1 min; 180 °C / 4 h | FDA ITG “650 C for 1 minute or 180 C for 4 hours, likewise, will destroy pyrogens”[2] |
| Lower-temperature caution | 170 °C | FDA ITG “at lower temperatures (of 170 C), thermal destruction follows second-order rate, and a 3 log reduction of endotoxin levels at lower temperatures might not be practical”[2] |
Rows marked check source are values this page will not publish as a single figure because the sources available to us disagree or are edition-dependent. Verify against the pharmacopoeial text current at your site.
Inside a vial depyrogenation tunnel
A continuous sterilising and depyrogenating tunnel sits between the vial washer and the filling line, and it is the only barrier in that chain that destroys endotoxin. Three zones in sequence: a pre-heating zone that warms the containers, a hot zone that delivers the depyrogenation effect, and a cooling zone that returns them to a fillable temperature under Grade A air[7]. Tap or click a zone in the diagram to highlight its row in the specification table below.
Zone specification and failure modes
| Zone | Function | What is qualified | Common failure |
|---|---|---|---|
| 1 — Pre-heating | Warms containers and evaporates residual wash water before they enter the hot zone | Inlet temperature profile, exhaust balance, absence of condensate carry-over | Wet vials entering the hot zone, which depresses the achieved temperature at the container surface |
| 2 — Hot zone | Delivers the depyrogenation effect. Reported operating range 220 to 350 °C[7] | Heat distribution, heat penetration to the container, accumulated lethality, endotoxin challenge recovery | Overloaded belt restricting hot-air circulation; cold spot never identified because distribution mapping used too few thermocouples |
| 3 — Cooling | Returns containers to a fillable temperature under Grade A air | HEPA integrity, air classification at the outfeed, pressure differential against the filling room | Recontamination at the outfeed because the pressure cascade reverses during a door interlock event |
Worst-case challenge conditions are the opposite of comfortable ones: ISPE describes worst-case testing using “increased belt speed and lower temperature set point”[7]. Sterile-area airflow behaviour upstream of this equipment is covered in our guide to HVAC system components and working principle.
Depyrogenation methods compared
USP splits depyrogenation into separate general chapters by mechanism, and the split is useful because the validation evidence differs completely between them.
Dry heat — USP ⟨1228.1⟩
The default for glass vials, ampoules, stainless steel change parts and any component that tolerates the temperature. Destroys the endotoxin molecule rather than removing it, which is why it is the only route that leaves nothing to be carried forward. Validated either by demonstrated 3-log reduction on challenged units[1] or by accumulated lethality not less than 30[4].
Applies to: glass containers, metal parts, heat-stable powders. Does not apply to: elastomeric closures, most plastics, aqueous solutions, biologics.
Filtration — USP ⟨1228.3⟩
Removes endotoxin from a liquid rather than destroying it, using ultrafiltration or charge-modified media[6]. The critical design question is whether the product molecule passes the membrane while the lipopolysaccharide is retained, which makes this route product-specific in a way dry heat is not.
Applies to: heat-labile solutions, buffers, some APIs. Validation evidence: spiked-feed challenge with recovery across the filter, plus extractables and product-adsorption data. Never transferable between products.
Rinsing — USP ⟨1228.4⟩
Dilution rather than destruction. FDA states that “normally, depyrogenation can be achieved by multiple rinses of hot WFI”[1], and the FDA inspection technical guide sets the expectation for the dilution route as “at least a 3 log reduction below the endotoxin challenge when the dilution process is employed”[2].
The dependency people miss: a rinse route is only as good as the rinse water. If the final rinse is at the WFI limit of 0.25 EU/mL[2], the rinse cannot take the surface below the water. Your water system qualification becomes part of your depyrogenation validation — see FDA guidelines for high-purity water systems.
Chemical, chromatographic and radiation routes
Alkali or oxidising treatment, affinity and ion-exchange chromatography, and distillation all appear in the literature. In a finished-dosage sterile facility they are usually confined to specific API or equipment-cleaning contexts rather than container preparation.
Ionising radiation is not a depyrogenation method. Gamma and e-beam are sterilization processes. A gamma-irradiated ready-to-use component is supplied sterile and its non-pyrogenic status rests on the supplier’s own depyrogenation step upstream — which is a supplier qualification question, and belongs in your vendor audit file, not in your tunnel protocol.
Which route does your material need?
Select the material and the outcome you need. The verdict names the process and the control point that governs it.
1. Material
2. Required outcome
Choose one option from each group
The verdict names the process route and the parameter your protocol has to control.
SOP: depyrogenation validation of a sterilising tunnel or oven
An adaptable template. It is written for a dry heat tunnel or batch oven used to depyrogenate primary glass containers, and it assumes the FDA endotoxin-challenge acceptance route. If your site runs the USP lethality route instead, replace section 7 with the F-value calculation and state that decision in section 3.
1. Purpose
To define the procedure for performance qualification of a dry heat sterilising and depyrogenating tunnel or oven, so that the equipment is demonstrated to reduce bacterial endotoxin on primary glass containers to the acceptance criterion stated in section 7.
2. Scope
Applies to dry heat tunnels and batch ovens used for primary glass containers at the site. It does not cover moist heat sterilisation of equipment or filter housings, depyrogenation of liquids by filtration or rinsing, terminal sterilisation of finished product, or the qualification of the vial washer upstream, each of which is governed by its own protocol.
3. Responsibility
- Officer, Validation: writes the protocol, executes the runs, compiles the raw data.
- Officer, Quality Control (Microbiology): supplies and recovers endotoxin indicator units, performs the bacterial endotoxins test, reports recovery on positive controls.
- Engineer, Production: sets belt speed and set points, confirms loading pattern, confirms calibration status of tunnel instrumentation.
- Head, Quality Assurance: approves the protocol before execution, approves the report, decides on any deviation, and defines the requalification interval as site policy.
4. Materials and equipment
- Calibrated thermocouples, minimum count defined by the tunnel manufacturer’s mapping recommendation, each with a valid calibration certificate traceable to a national standard, calibrated before and after the run.
- Data acquisition system with a scan interval short enough to resolve the exposure period.
- Endotoxin indicator units at a defined nominal loading. ISPE describes challenge studies inoculating containers with, for example, 5000 endotoxin units[7]. check source USP ⟨1228.5⟩ governs endotoxin indicators[6]; take the loading and its tolerance from the current chapter text and the supplier’s certificate of analysis, not from this page.
- Reagents for the bacterial endotoxins test, within expiry, with a valid standard curve.
- Depyrogenated glassware and pyrogen-free water for the recovery step.
5. Procedure
6. Frequency
Initial performance qualification before routine use. Requalification after any change to the equipment, the loading pattern, the container format or the cycle parameters, and at a periodic interval. site policy The periodic interval is set by the site quality system and its change control and periodic review procedure. It is not a fixed compendial number, and a protocol that presents an annual interval as a regulatory requirement is misstating its own basis.
7. Acceptance criteria
| Parameter | Criterion | Basis |
|---|---|---|
| Endotoxin reduction on challenged units | NLT 3 log (99.9%) | FDA 2004 aseptic processing guidance[1] |
| Residual endotoxin per sample (USP commentary route) | NMT 0.1 EU | USP commentary on ⟨1228.1⟩[5] |
| Accumulated lethality, if the USP route is adopted instead | NLT 30 | USP ⟨1228.1⟩ no endotoxin challenge required above this[4] |
| Positive control recovery | check source | check source the recovery window is defined by USP ⟨1228.5⟩ and the indicator supplier’s certificate[6]. We have not published a figure here because the chapter text is not openly available; take it from the edition current at your site |
| Number of successful consecutive runs | 3 | site policy conventional validation practice, not a compendial number |
| Thermocouple drift, pre versus post run | per protocol | site policy set the tolerance in the protocol before execution and justify it |
Rows marked site policy are internal convention, not a pharmacopoeial requirement. Rows marked check source are values this page deliberately does not publish.
8. Precautions
- Endotoxin indicator units are consumables with an expiry and a storage condition. An expired unit invalidates the run, and this is a frequent avoidable failure.
- Do not open the tunnel during a qualification run to reposition a thermocouple. The run is void; restart it and record the deviation.
- Handle recovered units in depyrogenated glassware only. Endotoxin contamination introduced during extraction is indistinguishable in the result from a tunnel failure.
- Do not report a result from a run where positive control recovery failed. A “pass” derived from a failed positive control is a data integrity finding, not a technical one.
- The hot zone operates at temperatures that will cause immediate severe burns. Follow the site lockout procedure before any access.
9. Deviation handling
- Challenged unit fails the acceptance criterion. Quarantine any product filled from containers processed on that configuration since the last successful qualification. Raise a deviation and investigate loading pattern, belt speed, thermocouple drift and indicator storage before repeating.
- Positive control does not recover. The run is invalid. Investigate the extraction step and the reagents. Do not treat the challenged unit results as evidence of anything.
- One of three runs fails. Do not carry forward the two passing runs. Complete the investigation, implement the correction, and execute three fresh consecutive runs.
- Thermocouple drifts beyond tolerance on the post-run check. Exclude that channel and assess whether the remaining channels still cover the mapped cold spot. If they do not, the run does not support a conclusion.
10. Annexure-I: endotoxin challenge recovery record
| Run | Position ID | Nominal load (EU) | Positive control recovered (EU) | Post-cycle result (EU) | Log reduction | Pass/Fail | Done by | Checked by |
|---|---|---|---|---|---|---|---|---|
Copies as tab-separated text. Paste directly into a spreadsheet.
11. Annexure-II and revision history
- Annexure-II: Thermocouple position drawing and calibration record.
- Annexure-III: Heat distribution and penetration raw data summary.
| Version | Effective | Change | Reason |
|---|---|---|---|
| 00 | DD-MMM-YYYY | New document | First issue |
| 01 | DD-MMM-YYYY | ___ | ___ |
This procedure is a template for adaptation. It requires local qualification, validation and Quality Assurance approval before use, and every acceptance criterion must be verified against the pharmacopoeial edition current at your site. Pharmacopoeial texts and Indian statutory instruments change between editions.
Six findings that fail a depyrogenation validation review
- Citing Annex 1 for the 3-log criterion. The number is FDA’s[1]. Annex 1 does not contain it[3]. A protocol that misattributes its own acceptance criterion invites a closer read of everything else in it.
- Calculating log reduction against the label claim. The denominator is the recovered positive control, not the nominal loading printed on the supplier’s box. Recovery is never 100 percent, and using the label claim quietly inflates the reported reduction.
- Mapping on an empty tunnel and stopping there. Heat distribution locates the cold spot; heat penetration proves the container actually reached temperature under load. A protocol with only distribution data has not demonstrated the process[7].
- Qualifying the comfortable case. Worst case means the highest belt speed and the lowest set point that routine production is permitted to use[7]. Qualifying at the nominal set point leaves the routine operating window unsupported.
- Assuming an autoclave load is depyrogenated. Moist heat is a sterilization process. Endotoxin is more heat-resistant than spores[4], and the autoclave cycle does not address it.
- Presenting a requalification interval as a regulatory requirement. The interval is set by the site quality system. Stating it as a compendial obligation misdescribes its own basis, and the correction usually reveals that no periodic review procedure actually governs it.
Endotoxin testing and the limits behind it
Depyrogenation validation is only as good as the test that measures it. The bacterial endotoxins test quantifies endotoxin against a reference standard; the recovered value from a challenged unit is what the whole exercise turns on. Two figures anchor the wider system.
| Water grade | Endotoxin limit | Source |
|---|---|---|
| Water for Injection, Sterile Water for Injection, Sterile Water for Irrigation | 0.25 EU/mL | FDA ITG[2] |
| Bacteriostatic Water for Injection, Sterile Water for Inhalation | 0.5 EU/mL | FDA ITG[2] |
Product-specific endotoxin limits are calculated from the maximum human dose per kilogram and the applicable threshold pyrogenic dose, so they are not a single number and must be derived for each product. If your route depends on rinsing rather than dry heat, the water system is inside the validated boundary and its endotoxin performance has to be qualified alongside the process itself. Facility-level expectations for that sit in our summary of MHRA guidelines for quality in pharmaceutical manufacturing and the CDSCO Schedule M compliance dashboard.
Frequently asked questions
Only in one direction, and only for dry heat. Bacterial endotoxin is more resistant to dry heat than the most heat-resistant bacterial spores, so a dry heat cycle sufficient for depyrogenation will also reliably sterilize the load. The reverse does not hold: a moist heat autoclave cycle at 121 degrees Celsius destroys spores while leaving endotoxin substantially intact, so an autoclaved item is sterile but not depyrogenated.
No. The 2022 revision of Annex 1 contains no occurrence of the phrase log reduction. The three-log criterion comes from the FDA 2004 guidance on sterile drug products produced by aseptic processing, which asks that validation data demonstrate a reduction in endotoxin content of at least 99.9 percent. Annex 1 addresses depyrogenation operationally, naming the depyrogenation oven or tunnel as a double-ended pass-through route into the clean area, and requires that endotoxin and pyrogen contamination on primary containers be appropriately controlled.
Under the USP lethality route, yes. USP states that a process yielding an accumulated dry heat lethality of not less than 30 minutes during the exposure period requires no endotoxin challenge, on the basis that such a process demonstrates roughly a six-log reduction of the most resistant reference standard endotoxin reported. That route depends entirely on thermocouple data you can defend, so the evidence burden moves from microbiology to thermal mapping rather than disappearing.
Because the dry heat lethality value is defined against that temperature. One unit of depyrogenation lethality is the effect of one minute at 250 degrees Celsius, so a hold of 30 minutes at that temperature accumulates a total of 30 units. It is a widely used cycle rather than a mandatory one; tunnels in practice run hot zones reported between 220 and 350 degrees Celsius, with the residence time set by belt speed to deliver the required accumulated effect.
They do not go through the tunnel. Elastomeric closures are washed and rinsed, and depyrogenation is achieved by dilution rather than destruction, which is why the endotoxin quality of the final rinse water becomes part of the validated process. FDA states that depyrogenation can normally be achieved by multiple rinses of hot Water for Injection, and its inspection guidance expects at least a three-log reduction below the endotoxin challenge where the dilution route is used. Ready-to-use closures supplied sterile and non-pyrogenic shift that burden to supplier qualification.
There is no compendial interval. Requalification is triggered by change: equipment modification, a new container format, a change to loading pattern, belt speed or set point, or a relevant deviation. Sites additionally set a periodic interval through their own change control and periodic review procedure, and many choose annually. Presenting that internal interval as a regulatory requirement is a common protocol error, because it misstates the basis of the site’s own commitment.
Reviewing a validation package before an inspection?
Misattributed acceptance criteria, worst-case definitions that were never worst case, and requalification intervals with no governing procedure are the three most repeatable findings in this area — and all three are visible on a documentation read, before anyone walks the line. Laafon Galaxy offers pharmaceutical regulatory compliance consultation covering protocol and report review for sterile-area qualification. Sterile facility layout and equipment scoping is handled separately under our plant setup cost assessment.
Related on laafon.com
- Principle of autoclave — the moist heat side of the comparison, and why it is a sterilization process only.
- SOP for dry powder filling operation (injectable vials) — what happens to the containers immediately after the cooling zone.
- FDA guidelines for high-purity water systems — WFI and purified water specifications, relevant wherever the rinse route is used.
- SOP for fumigation of microbiology lab — the QC-side counterpart for area decontamination.
- Injectable dosage forms — the product categories this equipment chain serves.
- All SOPs on laafon.com — the full standard operating procedure library.
References
- US Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. Rockville (MD): FDA; 2004. Available from: https://www.fda.gov/media/71026/download. Accessed September 2026.
- US Food and Drug Administration. Inspection Technical Guide: Bacterial Endotoxins/Pyrogens. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/bacterial-endotoxinspyrogens. Accessed September 2026.
- European Commission. EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products. Brussels: European Commission; 22 August 2022, effective 25 August 2023. Available from: https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf. Accessed September 2026.
- United States Pharmacopeia. General Chapter ⟨1228.1⟩ Dry Heat Depyrogenation [chapter text as circulated in 2014; third-party hosted copy]. Available from: lifescientia.com. Verify against the USP-NF edition current at your site. Accessed September 2026.
- US Pharmacopeia. Depyrogenation chapters commentary. American Pharmaceutical Review Endotoxin Supplement; 2017. Available from: https://www.acciusa.com/pdfs/supplements/Endotoxin Detection Part V/US_Pharmacopeia.pdf. Accessed September 2026.
- United States Pharmacopeia. General Chapters ⟨1228.3⟩ Depyrogenation by Filtration, ⟨1228.4⟩ Depyrogenation by Rinsing and ⟨1228.5⟩ Endotoxin Indicators for Depyrogenation. USP-NF. Available from: https://doi.usp.org/USPNF/USPNF_M10256_01_01.html (subscription required for full text). Accessed September 2026.
- International Society for Pharmaceutical Engineering. Validation of a Depyrogenation Tunnel. iSpeak blog. Available from: https://ispe.org/pharmaceutical-engineering/ispeak/validation-depyrogenation-tunnel. Secondary source. Accessed September 2026.
- International Organization for Standardization. ISO 17665:2024 Sterilization of health care products — Moist heat — Requirements for the development, validation and routine control of a sterilization process for medical devices. Geneva: ISO; 2024. Available from: https://www.iso.org/standard/80271.html. Accessed September 2026.
- International Organization for Standardization. ISO 20857:2010 Sterilization of health care products — Dry heat — Requirements for the development, validation and routine control of a sterilization process for medical devices. Geneva: ISO; 2010. Available from: https://www.iso.org/standard/39778.html. Accessed September 2026.
- Parenteral Drug Association. Technical Report No. 3 (Revised 2013): Validation of Dry Heat Processes Used for Depyrogenation and Sterilization. Bethesda (MD): PDA; 2013. Available from: https://www.pda.org/bookstore/product-detail/2019-tr-3-revised-2013-validation-of-dry-heat-processes. Accessed September 2026.
- Tsuji K, Harrison SJ. Dry-heat destruction of lipopolysaccharide: dry-heat destruction kinetics. Appl Environ Microbiol. 1978;36(5):710-714. Available from: https://journals.asm.org/doi/pdf/10.1128/aem.36.5.710-714.1978. Accessed September 2026.
- F Value Requirements for the Destruction of Endotoxin in the Validation of Dry Heat Sterilization/Depyrogenation Cycles. PDA J Pharm Sci Technol. 1982;36(1):23. Available from: https://journal.pda.org/content/36/1/23. Accessed September 2026.
Technical and educational content only. Not medical, legal or investment advice. Pharmacopoeial texts, ISO standards and Indian statutory instruments are revised between editions; every limit, chapter number and acceptance criterion above must be verified against the edition current and applicable at your site before it is used in a protocol. Where this page marks a value check source, no figure has been published because the primary text was not openly retrievable or the available sources disagree.
